Company intelligence / Profile preview

ImmunogenX

California, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Latiglutenase has demonstrated histologic protection and symptom reduction in celiac disease patients in Phase 2 trials, showing significant efficacy and safety as an adjunct to a gluten-free diet. The program has completed two Phase 2 trials and is considered Phase 3-ready for celiac disease[1][4][5][6].

Therapeutic areas: Gastroenterology
Modalities: Enzyme replacement therapyBiologicRecombinant protease
Industry: Biotech

Partnerships

First Wave BioPharma (acquirer)

Beyond the preview

Go deeper on ImmunogenX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunogenX.

Explore the full profile